Skip to main content
. 2019 Jul 1;15(3):183–190. doi: 10.5152/ejbh.2019.4761

Table 1.

Summary of changes in adjuvant therapy recommendations with Oncotype DX testing in the modelling analysis

Recurrence Score Initial recommendation Post Oncotype DX net change in CT use
HT+CT (%)

HT (%) HT+CT (%)
Low 30.9 (51/165) 25.5 (42/165) −21.0
Intermediate 11.5 (19/165) 23.6 (39/165) 1.9
High 1.8 (3/165) 6.7 (11/165) 4.8
Total 44.2 (73/165) 55.8 (92/165)

CT: chemotherapy; HT: hormone therapy